Trial Profile

An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ribociclib (Primary) ; Anastrozole; Exemestane; Letrozole; Tamoxifen
Indications Adenocarcinoma; Early breast cancer; HER2 negative breast cancer; Male breast cancer
Focus Adverse reactions
Acronyms EarLEE-1
Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals

23 Jan 2021 This trial has been Discontinued in Netherlands, according to European Clinical Trials Database record.
26 Oct 2020 This trial has been Discontinued in Czech Republic, according to European Clinical Trials Database record.
02 Oct 2020 This trial has been discontinued in Netherlands, according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com